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Abstract
Background: Inflammation is associated with Aβ pathology in Alzheimer's disease (AD) and
transgenic AD models. Previously, it has been demonstrated that chronic stimulation of the
immune response induces pro-inflammatory cytokines IL-1β and TNF-α which contribute to
neurodegeneration. However, recent evidence has shown that inducing the adaptive immune
response reduces Aβ pathology and is neuroprotective. Low concentrations of IFN-γ modulate the
adaptive immune response by directing microglia to differentiate to antigen presenting cells. Our
objective was to determine if exercise could induce a shift from the immune profile in aged (17–19
months) Tg2576 mice to a response that reduces Aβ pathology.
Methods: TG (n = 29) and WT (n = 27) mice were divided into sedentary (SED) and exercised
(RUN) groups. RUN animals were provided an in-cage running wheel for 3 weeks. Tissue was
harvested and hippocampus and cortex dissected out. Quantitative data was analyzed using 2 × 2
ANOVA and student's t-tests.
Results: IL-1β and TNF-α were significantly greater in hippocampi from sedentary Tg2576 (TGSED)
mice than in wildtype (WTSED) (p = 0.04, p = 0.006). Immune response proteins IFN-γ and MIP-1α
are lower in TGSED mice than in WTSED (p = 0.03, p = 0.07). Following three weeks of voluntary
wheel running, IL-1β and TNF-α decreased to levels indistinguishable from WT. Concurrently, IFN-
γ and MIP-1α increased in TGRUN. Increased CD40 and MHCII, markers of antigen presentation,
were observed in TGRUN animals compared to TGSED, as well as CD11c staining in and around
plaques and vasculature. Additional vascular reactivity observed in TGRUN is consistent with an
alternative activation immune pathway, involving perivascular macrophages. Significant decreases in
soluble Aβ40 (p = 0.01) and soluble fibrillar Aβ (p = 0.01) were observed in the exercised transgenic
animals.
Conclusion: Exercise shifts the immune response from innate to an adaptive or alternative
response. This shift in immune response coincides with a decrease in Aβ in advanced pathological
states.
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Background
Successful long-term treatment for Alzheimer's disease
(AD) has remained as elusive as the disease's cause. Life-
style treatments for AD, such as exercise, are being
researched in both animal and human models [1-5]. Exer-
cise has been found to be a successful preventative meas-
ure in delaying disease onset. Exercise interventions in
patients who already exhibit AD symptoms have had
mixed results, but are able to show improvement to vary-
ing degrees [2-5].
The pathology in AD is well-known. Aβ and tau deposits
are the chief pathological hallmarks. Aβ has been impli-
cated in impairing learning and memory [6-10]. Aβ depo-
sition stimulates a local immune response by the
microglia, which become macrophagic [11-13]. The mac-
rophagic phenotype in AD is characterized by the pres-
ence of CD11b and immunohistochemistry revealing
attempted phagocytosis of Aβ [11,14-16]. This response is
not sufficient to clear Aβ deposits and instead contributes
to the chronic progression of AD [17-19]. Chronically
activated microglia are characterized by their macrophagic
morphology, CD11b expression, and release of neuro-
toxic cytokines IL-1β and TNF-α [20,21]. This response of
microglia seems to contribute to AD progression, rather
than clearing Aβ pathology [22-24].
However, the immune responses possible in the brain are
more complex than was once thought. Aside from the ini-
tial innate response, characterized by macrophagic micro-
glia and cytokine production, adaptive responses in which
antigen is presented to T cells infiltrating from the periph-
ery has been increasingly observed in various neurodegen-
erative disease states and in Aβ vaccination studies [14,25-
28]. In addition, exciting new evidence exists of an alter-
native immune response, characterized by perivascular
cells that participate in both innate immunity, via phago-
cytosis and cytokine production, as well as adaptive
immunity via antigen presentation and co-stimulation at
the blood brain interface [29-31]. Evidence indicates that
the AD brain is capable of clearing Aβ if the microglial
response is manipulated [32]. For instance, injected bone
marrow cells travel to the brain and differentiate into
microglia. These newly differentiated microglia acquire a
dendritic, rather than macrophagic phenotype and are
associated with antigen presentation and a decrease in Aβ
[32]. Further, microglia stimulated with glatiramer acetate
or IFN-γ change phenotype and become antigen present-
ing cells [33-35]. This antigen presenting phenotype stim-
ulates the adaptive immune response, characterized by
increased major histocompatibility complex II (MHCII)
expression and CD11c positive cells [34,36]. Butovsky et
al.(2007) and Ziv et al (2006) have also shown this shift
to the adaptive immune response coincides with
decreases in cytokines associated with the innate immune
response, namely IL-1β and TNF-α [34,37]. The identity
of the antigen presenting cells was initially unclear in
these studies. However, it has recently been suggested that
the clearance of Aβ is dependent on invasion of the brain
by peripheral monocytes, which differentiate into antigen
presenting microglia [35,38]. A stimulus to the immune
response in late AD may confer benefit through clearance
of soluble species of Aβ, as evidenced in several studies
using lipopolysaccharide or Aβ immunization [39-41].
The role of microglia in AD is clearly complex and can be
either detrimental or beneficial, depending on the nature
of the microglial response.
While physical exercise can delay the onset of cognitive
decline in AD, the mechanisms remain largely unknown
[42-46]. Adlard et al. recently demonstrated that exercise
reduced Aβ deposition in AD transgenic mice [1]. We sug-
gest that exercise may be also altering the immune
response in AD, which in turn affects Aβ levels. We
hypothesize that the protective effects of exercise in AD
may be due in part to an immune shift from innate to
antigen presenting, similar to the shift observed by
Butovsky et al (2005–2007) [33,35]. Specifically, we
hypothesize that this shift is characterized by decreases in
markers of the innate response, such as TNF-α and IL-1β,
as well as increases of adaptive and alternative activation
response stimulating cytokine IFN-γ. We further suggest
that exercise induces a microglial phenotype shift from a
macrophagic phenotype to an antigen presenting pheno-
type, expressing CD11c and MHC II. We also expect to see
increased CD40, which communicates from the antigen
presenting cell to CD40 ligand on T cells. It is possible this
shift in immune response could decrease Aβ species in the
Tg2576 mouse, as seen in the Butovsky studies [33-
35,38]. In contrast to Butovsky, our study is unique in that
we examined whether physical exercise can induce this
immune shift without pharmacological intervention.
In the current study, we used the Tg2576 AD mouse
model developed by Karen Hsiao [47]. Tg2576 mice
exhibit plaque pathology at 10 months, but show cogni-
tive deficits as early as 6 months [8,48]. For the present
study, we were interested in using aged mice with
advanced pathology and memory deficits. The older
mouse with advanced pathology serves as a model for
later stages of AD. We have previously demonstrated that
three weeks of voluntary running improved water maze
performance in aged (17–19 month) Tg2576 mice [49].
In this investigation, we examine a shift in the immune
response to Aβ as a potential mechanism for the behavio-
ral improvements.Journal of Neuroinflammation 2008, 5:13 http://www.jneuroinflammation.com/content/5/1/13
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Methods
Animals
The University of California, Irvine's Institutional Care
and Use Committee approved all animal protocols. We
used C57Bl6/SJL (WT) and Tg2576 (TG) from an estab-
lished colony (ca. 2000) at University of California,
Irvine. We assigned Tg2576 (n = 29) and C57Bl6/SJL (n =
27) to cages containing exercise wheels (RUN) or size
matched cages without wheels (SED) at 16–18 months of
age, singly-housed. We provided RUN animals with run-
ning wheels for 3 weeks and monitored their running via
software (Minimitter).
We sacrificed RUN animals along with SED animals by
decapitation. We then dissected hippocampi and cortices
in physiological saline solution (145 mM NaCl, 4.7 mM
KCl, 2 mM CaCl, 1 mM MgSO4, 4 mM MOPS, 1 mM
NaH2PO4, 5 mM glucose, 2 mM pyruvic acid, 20 μM
EDTA; pH 7.4), placed in microfuge tubes on dry ice, and
stored frozen at -80°C. Frozen tissue was prepared by pul-
verization on dry ice. Pulverized tissue was soniccated in
cell lysis buffer (Bio-Rad) according to Hulse et al. [50].
Protein content determined by bichondruric acid method
(Bio-Rad, Hercules, CA).
Cytokines
Bio-plex multi-plex analysis (Bio-Rad, # X600063YDF)
was performed according to manufacturer's instructions
in a custom kit designed to detect multiple cytokines. The
bio-plex technology uses polystyrene beads internally
dyed with differing ratios of two spectrally distinct fluoro-
phores. Dyed beads are labeled with antibodies for each
cytokine and the antibody-conjugated beads are allowed
to react with sample and a secondary antibody in a 96-
well plate to form a capture sandwich immunoassay. The
assay solution is read by a Bio-Plex array reader, which
distinguishes the beads' spectral address. Using the
amount of green fluorescence emitted by the phycoeryth-
rin-tagged detection antibody, the array reader extrapo-
lates the concentration to the appropriate standard curve.
Multiplex technology allows us to look at many cytokines
within a single sample of tissue. We performed bio-plex
analysis on 24 animals (n = 6 per group). We validated
bio-plex findings for IFN-γ (BD Biosciences) and TNF-α
(BD Biosciences) by ELISA. Because IL-1β levels were
below detection sensitivity of the bio-plex assay, we also
performed an ELISA for IL-1β, using this data in statistical
analysis (Pierce).
Western blot
IFN-γ activates an antigen presenting phenotype in micro-
glia [34]. To further examine antigen presenting cell activ-
ity suggested by the cytokine profile observed in TGRUN vs.
TGSED, we examined CD40 and MHC II protein expres-
sion in the hippocampus via western blot. For CD40
detection, 15 μg of hippocampal lysates from a randomly
selected subset of animals (n = 8 TGRUN, n = 7 TGSED, n =
4 WTRUN, n = 9 WTSED) were prepared. Samples were pre-
pared in loading buffer and boiled 5 minutes, then elec-
trophoresed on 10% Tris-HCl ready-made gels (Bio-Rad)
along with a homogenized liver sample as a positive con-
trol. Proteins were transferred to PVDF membrane over-
night at 4°C. We blocked the membranes for 2 hours in
StartingBlock™ PBS buffer (Pierce). We incubated mem-
branes overnight at 4°C in 1:200 CD40 monoclonal anti-
body (BD Pharmingen, #550285) washed, and incubated
in HRP-conjugated secondary anti-rat antibody (Santa
Cruz, #sc-2065) 2 hours at 1:5000 in tris buffered saline
with 1% Tween-20. We washed the membranes exten-
sively, then used West Pico chemiluminescence to detect
antigens. Results were visualized on Pierce CL-Xposure™
blue film. Results were quantified using Image J freeware
as percent reactivity of CD40/β-actin (AbCam) and t-tests
between WTSED and TGSED, as well as TGSED and TGRUN
were performed.
Blots for MHC-II (1:100 BD-Pharmingen, #553538) were
run on TGSED (n = 8) and TGRUN (n = 8) following the
same procedure, using HRP-conjugated donkey anti-rab-
bit secondary antibody (1:1000, Jackson). Densitometric
values for MHC II were normalized to β-actin (1:1000,
SIGMA). Iba-1 (WAKO) was also used (1:2000) to probe
the membranes for general microglia reactivity using the
same basic paradigm. Iba-1 was quantified relative to β-
actin.
Aβ ELISA
It is not clear if an increase in adaptive immunity in the
hippocampus would lead to changes in levels of the path-
ological hallmark of AD, Aβ, in animals of such advanced
age. Cortical samples from TGSED (n = 5) and TGRUN (n =
6) were pulverized and then sonnicated in T-PER buffer
(PIERCE) (10 μl/mg tissue). Samples were centrifuged for
one hour at 100,000 g. Supernatant was removed and
saved as the soluble fraction at -80°C. The insoluble frac-
tion was resuspended in 70% formic acid and sonnicated.
It was then spun a second time at 100,000 g for one hour
and the formic acid layer (middle layer) removed and
stored at -80°C.
Brain samples were run in triplicate on 96-well Immulon
2-HB plates (Thermo Electron Corp., Milford, MA) coated
with a monoclonal anti-Aβ1–16 antibody at 25 ug/ml
(kindly provided by Dr. William Van Nostrand, Stony
Brook University, Stony Brook, NY) and detection was by
monoclonal HRP-conjugated antibodies anti-Aβ1–40  at
1:500 (MM32-13.1.1) and anti-Aβ1–42 at 1:1000 (MM40-
21.3.1) (kindly provided by Dr. Christopher Eckman,
Mayo Clinic Jacksonville, Jacksonville, CA). Detection
antibodies were visualized using the HRP-substrate 1-StepJournal of Neuroinflammation 2008, 5:13 http://www.jneuroinflammation.com/content/5/1/13
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Ultra TMB-ELISA buffer (Pierce, Rockford, IL). For stand-
ards, synthetic Aβ1–40 and Aβ1–42 (Bachem California, Inc.,
Torrance, CA) were used after a pretreatment with HFIP to
prevent fibril formation. Synthetic Aβ1–40 or Aβ1–42 were
prepared in the same buffer as the samples and Aβ values
were determined by comparison to the appropriate stand-
ard curve. The inclusion of a series of controls to test the
absorbance of buffers, samples, and both capture and
detection antibodies yielded negative results.
Aβ dot blots & multiplex
Aβ species were quantified by dot-blot analysis. Hippoc-
ampal lysates were prepared from TGSED (n = 5) and
TGRUN (n = 5) as described [8]. Wildtype samples (n = 2)
were used as negative controls. Protein concentrations
were determined by BCA (Pierce). An equal amount of
protein from each sample was spotted onto nitrocellulose
membranes (Schleicher and Schuell, 0.2 micron) and
membranes were blocked 90 minutes at room tempera-
ture and incubated with appropriate primary antibodies
(6E10 Covance, Princeton, NJ) and OC (kindly provided
by Charles Glabe) 60 min at room temperature. These
antibodies were used to assess total and fibrillar oligo-
meric Aβ, respectively. The OC antibody is conformation
specific (for a more detailed description, see Kayed et al,
2007) [51]. Membranes were then washed, incubated
with appropriate HRP-conjugated secondary (EMD
Chemicals, San Diego, CA) and visualized by ECL (Super-
signal West Pico, Pierce). Films were scanned and amyloid
levels were quantitated using NIH Image J Software.
Aggregated Aβ was also measured in the aforementioned
hippocampal samples and serum samples using multiplex
technology and the human aggregated beta amyloid kit
from Biosource/Invitrogen (catalog #LHB3491). The anti-
bodies contained in this kit are specific for the 12 subunit
oligomeric form of Aβ (also known as Amyloid Derived
Diffusible Ligand, ADDL, Aβ*
Immunohistochemistry
A small number of animals (n = 4 TGSED, n = 4 TGRUN, n
= 4 WTSED, n = 4 WTRUN) were perfused with paraformal-
dehyde and brains dissected for immunohistochemistry
for general microglia (CD11b) and dendritic (CD11c)
microglial markers colocalized with Aβ (CD11b, BD
Pharmingen; CD11c, Antigenix; Aβ, 6E10, Covance).
Macrophagic markers CD68 (DAKO) and perivascular
macrophage marker mannose receptor (HyCult Biotech-
nology) were used to identify macrophages and their rela-
tionship to CD11c+ cells and/or Iba-1 + microglia.
Results
No significant differences in running distances existed
between genotypes. (Table 1)
IL-1β and TNF-α protein were significantly greater in aged
sedentary Tg2576 mice (TGSED) than in sedentary
wildtype (WTSED) (IL-1β: p = 0.006; TNF-α: p = 0.04) (Fig-
ure 1). Three weeks of exercise decreased the levels of both
IL-1β and TNF-α to a point where they no longer signifi-
cantly differed from the WTSED. The IL-1β in exercised
Tg2576 mice (TGRUN) was significantly lower than in the
TGSED (p = 0.01)(Figure 1). When we compare current
cytokine markers to our previously published behavioral
data, the decreased levels of the pro-inflammatory
cytokine IL-1β observed in transgenic animals correlate
with decreased mean latency to find the escape platform
on day 2 of the radial arm version of the Morris water
maze (correlation = 0.31, p = 0.001)[49]. We observed
CD11b+ microglia in TGSED and TGRUN animals (Figure
2). Levels of microglial activation, as measured by Iba-1
western blot, did not change with exercise (Figure 2).
In contrast, IFN-γ was significantly lower in aged TGSED
than in WTSED (p = 0.02) and showed a trend to increase
in TGRUN (p = 0.06) such that it returned to levels similar
to the WT (Figure 3). Similarly, protein levels of chemok-
ine MIP1α that tended to be lower in the TGSED than the
WTSED (p = 0.07), were significantly increased in TGRUNan-
imals (p = 0.05) to levels similar to those observed in the
WT (Figure 3). The MHC II blots confirm that the IFN-γ
increase observed is associated with increased antigen
presentation in the TGRUN animals, who expressed signifi-
cantly more MHC II than TGSED (p = 0.04) (Figure 4). In
the TGRUN animals, we observed abundant antigen pre-
senting cells, indicated by CD11c (Figure 5B). In TGRUN,
we observed CD11c+ blood vessels and in individual cells
that appeared linearly arranged, as if inside of blood ves-
sels (Figure 5B,C). Vessels labeled strikingly with CD68
(red) in proximity to, but not within the same cells as
CD11c (green), suggesting alternatively activated macro-
phages may be present (Figure 5D–F). Vessels were dou-
ble labeled for Iba-1 (green) and mannose receptor (red),
a marker for perivascular macrophages (Figure 5G–I). No
Table 1: Swim speeds and wheel rotations. Swim speeds did not significantly differ between any groups. Number of wheel rotations 
per day did not differ between genotypes.
WTSED WTRUN TGSED TGRUN
Swim speed (m/s) 0.15 ± 0.02 0.16 ± 0.03 0.11 ± 0.03 0.18 ± 0.03
Wheel rotations/day n/a 4408 ± 783 n/a 3954 ± 877Journal of Neuroinflammation 2008, 5:13 http://www.jneuroinflammation.com/content/5/1/13
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IL-1β is significantly greater in sedentary Tg2576 mice than in WT sedentary mice (p = 0.006) Figure 1
IL-1β is significantly greater in sedentary Tg2576 mice than in WT sedentary mice (p = 0.006). Exercise results in a significantly 
lower level of IL-1β in the Tg2576 (p = 0.01). The level of IL-1β in exercised Tg2576 mice (TGRUN) is no longer distingushable 
from the WT mouse (WTSED). TNF-α is significantly greater in sedentary Tg2576 mice (TG sed) than in WT sedentary mice (p 
= 0.04). Exercise reduces TNF-α in TG mice (TG run) to a level indistinguishable from the WT (WTSED). *Significantly different 
from sedentary WT † significantly different from sedentary Tg2576.
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CD11b positive microglia (green immunofluorescence) in TGSED(A) Figure 2
CD11b positive microglia (green immunofluorescence) in TGSED(A). Higher magnification reveals some co-labeling with micro-
glial marker Iba-1 (red) (B, arrowheads). CD11b positive glia are present in TGRUN (C) and co-labeled with Iba-1 (red) in some 
cases (D, arrowheads). Overall levels of Iba-1 (normalized to actin) are not significantly different based on condition or geno-
type (E). High immunoreactivity for Iba-1 in WT is likely due to the advanced age of the animals used.Journal of Neuroinflammation 2008, 5:13 http://www.jneuroinflammation.com/content/5/1/13
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IFN-γ is significantly lower in the Tg2576 sedentary mice that in the WT sedentary mice (p = 0.03) Figure 3
IFN-γ is significantly lower in the Tg2576 sedentary mice that in the WT sedentary mice (p = 0.03). Exercise resulted in 
increased levels of IFN-γ in the Tg2576 mouse (TGRUN) to a level indistinguishable form the WT (WT). MIP-1α demonstrated 
a trend of being lower in TGSED compared to the WT (p = 0.07), but was significantly increased by exercise (TGRUN) (p = 0.05). 
*Significantly different from sedentary WT; † significantly different from sedentary Tg2576.
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MHC II levels were significantly greater in TGRUN than TGSED (p = 0.04) Figure 4
MHC II levels were significantly greater in TGRUN than TGSED (p = 0.04). CD40 is significantly greater in TGRUN compared to 
TGSED (p = 0.008). WTSED tended to have greater levels of CD40 than TGSED, but this difference failed to achieve significance (p 
= 0.10). † Significantly different from sedentary Tg2576.
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CD11c positive microglia (green immunofluorescence) are present in TGSED and colocalize with Iba-1 (arrowheads) but do not  appear vascular (A) Figure 5
CD11c positive microglia (green immunofluorescence) are present in TGSED and colocalize with Iba-1 (arrowheads) but do not 
appear vascular (A). CD11c labeling in TGRUN appeared in cells not labeled by Iba-1 (red) that were linearly arranged, perhaps 
within or around microvessels. (B, D). Larger vessels had CD11c labeling along the vessel wall, perhaps in the perivascular 
space (C). Using macrophage markers CD68, we observed microvascular labeling again only in TGRUN (D). Double labeling for 
CD11c (green) and CD68 (red) revealed that CD11c+ cells were adjacent to CD68+ cells in and around vasculature (arrows) 
(E, F). Using mannose receptor antibody (red), specific for perivascular macrophages, we again observed vascular labeling only 
in TGRUN (G-I). High magnification shows the mannose receptor labeled cells are within vessels (H, I)(arrowheads). Green indi-
cates Iba-1 labeling for microglia in and around vessels (G-I).Journal of Neuroinflammation 2008, 5:13 http://www.jneuroinflammation.com/content/5/1/13
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such cells or vessels were observed using the same markers
in TGSED animals.
The presence of MHCII and CD11c labeled cells indicate
antigen presentation. Increased MIP-1α levels suggest T
cells and monocytes are being recruited to the brain (Man,
2007). CD40, expressed by the antigen presenting cell
communicates with its ligand on T cells. In sedentary TG
animals, a trend of reduced expression of CD40 is present
compared to WTSED (p = 0.10), but there is a significant
elevation in CD40 from TGSED to TGRUN (p = 0.008)
(Figure 4). Additionally, alternative activation of macro-
phages could explain the shift in immune markers
observed [29]. Indeed, if we consider all of the cytokine
and chemokine changes collectively, along with the con-
flicting reports of T cell presence and function in the brain
[27], alternative activation of macrophages may be a more
likely candidate for repair in an AD state [52].
Finally, we examined whether exercise leads to reduced Aβ
in aged Tg2576 mice. We quantified the levels of various
Aβ species in cortex by ELISA, and in hippocampus and
serum using multiplex technology as well as dot blot.
Multiplex revealed no statistically significant differences
in Aβ aggregates in hippocampus, though direction of
change was to decrease in run (Figure 6A). There was no
detectable aggregated Aβ in the serum samples and immu-
nohistochemical staining for plaques appeared similar
between TGSED and TGRUN (data not shown). ELISA of
Aβ42 in soluble and insoluble fractions from cortex did
not statistically differ between TGSED and TGRUN though
we should note that there was a large degree of variation
between the RUN animals (Figure 6B–C) Total soluble
levels of Aβ40 did show a significant decrease (p = 0.01) in
theTGRUN animals compared to the TGSED (Figure 6B). Sol-
uble Aβ is composed of both fibrillar and pre-fibrillar oli-
gomeric species[51]. We used a conformation specific
fibrillar antibody to explore changes with exercise in the
Tg2576 [39].
The dot blots of hippocampal lysates are able to selec-
tively probe different soluble Aβ species in a soluble frac-
tion, spun at low speeds. First, we analyzed total Aβ using
6E10 on dot blots. We did not detect any significant dif-
ferences between SED and RUN (Figure 7A). The OC anti-
body detects soluble fibrillar Aβ that is conformationally
and immunologically distinct [51]. Levels of soluble Aβ
fibrils were 40% lower in TGRUN compared to TGSED as
assessed by OC antibody (Figure 7B). This decrease was
significant (p = 0.01).
Discussion
We have demonstrated that physical exercise can shift the
immune response in the brain of an AD mouse model. AD
is characterized by an innate immune response character-
ized by microglial activation. Though likely an intended
protective mechanism to phagocytose Aβ, these glia are
not capable of combating chronic AD pathology [53]. In
addition, the cytokines released by these microglia, IL-1β
and TNF-α, become cytotoxic when chronically expressed,
contributing to the overall neurodegeneration
[20,21,24,35,54-56]. We confirmed this immune state in
our sedentary aged TG animals. Our findings confirm pre-
vious findings that high IL-1β levels are correlated with
poor cognitive performance [57] and indicate that exer-
cise induces reductions in TNF-α and IL-1β in the hippoc-
ampus of Tg2576 mouse at advanced age.
Recent investigations into bone marrow derived cells that
differentiate into microglia in the brain, in concert with
studies where microglial phenotype is experimentally
altered to an antigen presenting phenotype collectively
suggest that if the adaptive immune response is stimu-
lated, Aβ pathology in AD can be reduced and cognition
improved [58,59,34,35,38]. The antigen presenting
response is characterized by CD11c positive cells, MHC II,
and CD40. IFN-γ has been shown to be a stimulus for this
microglial phenotype and has also been found to be capa-
ble of inducing Aβ clearance [37]. We demonstrate that
the aged TGSED mouse express lower levels of IFN-γ than
the WT and that exercise results in increased IFN-γ and
increased markers of the antigen presenting response. In
addition to antigen presenting microglia from the local
environment, it is also possible that exercise increases
recruitment of peripheral monocytes to the brain, where
they too can become antigen presenting cells. MIP-1α
recruits central and/or peripheral macrophages to the area
of plaque deposition in AD and MIP-1α was found to
increase in TGRUN[60,61]. However, the possibility of
peripheral recruitment is in debate, as recent data indi-
cates that much of the evidence in favor of monocyte
recruitment to the brain only occurs in the presence of
damage to the blood-brain barrier due to the whole-body
irradiation used in the original experiments [38,59,62-
64]. The integrity of the blood brain barrier is compro-
mised in AD and in the Tg2576 mouse model, however,
so we cannot rule out either a peripheral or central source
for these microglia [65-67]. Though the origin or the
microglia will be a topic for continued investigation, we
do demonstrate that the microglia present in the hippoc-
ampus after exercise in the aged TG mice exhibit character-
istics of the adaptive immune response and antigen
presentation.
Another interesting possibility presented by the vascular
localization of macrophagic markers observed in TGRUN
animals is the alternative activation of perivascular cells as
macrophages and antigen presenting cells. Though micro-
glia are the initial immune responders in the CNS,
perivascular cells may be more efficient at both phagocy-Journal of Neuroinflammation 2008, 5:13 http://www.jneuroinflammation.com/content/5/1/13
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Aβ analysis by multiplex and ELISA Figure 6
Aβ analysis by multiplex and ELISA. Aggregated Aβ levels are not significantly lower in hippocampus of TGRUN compared to 
TGSED, though a 35% decrease is observed in means. (A) Aβ40 but not Aβ42 is significantly lower in soluble fractions from cor-
tex of TGRUN and TGSED (p = 0.01)(B). There are no significant differences in insoluble fractions (C).
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tosis of antigen and presentation of that antigen than
adult microglia [25,68]. In particular, our data revealing
extensive mannose receptor labeling in TGRUN animals
strongly indicates perivascular macrophages are involved
in the immune response, as this receptor is not expressed
by microglia [31].
We suggest that the antigen being presented is Aβ or an Aβ
fragment. Fibrillar Aβ is a highly cytotoxic species that has
been shown to adhere to microglia [69,70]. If microglia
are stimulated to take on an antigen presenting pheno-
type, fibrillar Aβ can be cleared from the brain [53]. In the
current study, soluble Aβ40 and soluble fibrillar Aβ signif-
icantly decreased after three weeks of running coincident
with the increase in adaptive immune markers and the
improvement in behavior [49]. We also observed CD11c
adjacent to mannose receptor and CD68 positive cells
within the vasculature of TGRUN. This presence of perivas-
cular macrophages in conjunction with markers of anti-
gen presentation might be indicative of clearance of Aβ
into the periphery, supporting the "peripheral sink"
hypothesis, in which Aβ is proposed to efflux from brain
into plasma after immunization therapy [71-73]. Indeed,
one proposed function of the mannose receptor which we
Aβ analysis by dot blot Figure 7
Aβ analysis by dot blot. No differences existed between TGSED and TGRUN for total Aβ in the soluble fraction of hippocampal 
samples, evaluated by 6E10 antibody (A). Aβ fibrils, detected by OC antibody, were significantly decreased in TGRUN animals 
compared to TGSED (p = 0.01)(B). A representative dot blot is shown (C).
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observed in TGRUN is antigen transport [31]. Vasilevko et
al. (2007) recently showed that direct immunotherapy
with anti-Aβ antibodies resulted in decreased diffuse Aβ
deposits in brain, but increased Aβ40 in plasma [40].
In this study, we present evidence that exercise decreases
the chronic pro-inflammatory response well known to
associate with AD. The decrease in at least one of the
cytokines, IL-1β, correlates with improved ability to solve
a water maze task. Unlike ibuprofen and other anti-
inflammatory drugs used in AD treatment, which decrease
pro-inflammatory markers, the current study provides evi-
dence that exercise not only decreases pro-inflammatory
markers like IL-1β and TNF-α, but also increases adaptive
inflammatory markers IFN-γ, CD40, MHC II, CD11c, and
MIP-1α. We observed multiple macrophage markers
(CD68, mannose receptor) in and around the vasculature
of TGRUN animals. Further, we have shown that exercise
decreases soluble Aβ40 and soluble fibrillar Aβ. We sup-
port the hypothesis put forward by Butovsky et al (2006)
that the innate immune response in AD becomes dysfunc-
tional after chronic activation, but that an initiation of the
adaptive or alternative immune response may reduce
pathology [35]. The decrease in fibrillar Aβ and improve-
ment in behavior observed in our investigations of the
Tg2576 mouse at 17–19 months of age suggests that phys-
ical exercise can trigger this immune shift in late stages of
AD, leading to cognitive improvement [49].
Conclusion
Our data suggests that exercise intervention may pave the
way for successful Aβ clearance even in late stages of AD.
We suggest that exercise not only decreases neurotoxic
cytokines, but also increases Aβ clearance through its
induction of an adaptive or alternative immune response.
In summary, our investigation opens a potential avenue
for behavioral interventions that would be complemen-
tary to long term NSAIDs or anti-inflammatory drugs.
List of abbreviations
WT: Wildtype; TG: Transgenic; SED: Sedentary; AD: Alzhe-
imer's disease; IL: Interleukin; TNF: Tumor necrosis factor;
MHC: Major histocompatibility complex; IFN: Interferon;
MIP: Macrophage inflammatory protein; CNS: Central
nervous system; NSAIDS: Non-steroidal anti-inflamma-
tory drugs.
Competing interests
CGG is a consultant for Kinexis, Inc. The remaining
authors declare that they have no competing interests.
Authors' contributions
KEN designed and implemented the investigation and
was responsible for data analysis, interpretation, and
preparation of the manuscript. WWP performed the for
Aβ dot blots. AIP aided in study design and preparation of
tissue for histology. DHC provided Aβ ELISA data and
contributed to the direction of the investigation and data
interpretation. CGG created the unique antibodies used to
assess Aβ in the dot blot analysis. CWC contributed to the
writing of the manuscript and the data interpretation.
Acknowledgements
The authors would like to thank Hyun Jin Kim and Dr. Vitaly Vasilevko for 
assisting with the Aβ ELISAs. We wish to acknowledge Mr. Rick Muth for 
his generous support and Mary Brodey of Invitrogen for supplying the Aβ 
aggregate kits. We thank NIAMSD and NIA for their supporting grants 
AR047752 and AG000538
References
1. Adlard PA, Perreau VM, Pop V, Cotman CW: Voluntary exercise
decreases amyloid load in a transgenic model of Alzheimer's
disease.  J Neurosci 2005, 25(17):4217-4221.
2. Dishman RK, Berthoud HR, Booth FW, Cotman CW, Edgerton VR,
Fleshner MR, Gandevia SC, Gomez-Pinilla F, Greenwood BN, Hillman
CH, Kramer AF, Levin BE, Moran TH, Russo-Neustadt AA, Salamone
JD, Van Hoomissen JD, Wade CE, York DA, Zigmond MJ: Neurobi-
ology of exercise.  Obesity (Silver Spring) 2006, 14(3):345-356.
3. Etnier JL, Caselli RJ, Reiman EM, Alexander GE, Sibley BA, Tessier D,
McLemore EC: Cognitive performance in older women rela-
tive to ApoE-epsilon4 genotype and aerobic fitness.  Med Sci
Sports Exerc 2007, 39(1):199-207.
4. Teri L, Gibbons LE, McCurry SM, Logsdon RG, Buchner DM, Barlow
WE, Kukull WA, LaCroix AZ, McCormick W, Larson EB: Exercise
plus behavioral management in patients with Alzheimer dis-
ease: a randomized controlled trial.  Jama 2003,
290(15):2015-2022.
5. Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P,
Kukull W: Exercise is associated with reduced risk for incident
dementia among persons 65 years of age and older.  Ann Intern
Med 2006, 144(2):73-81.
6. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS,
Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid
beta protein potently inhibit hippocampal long-term poten-
tiation in vivo.  Nature 2002, 416(6880):535-539.
7. Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW,
Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG: Dimeric
amyloid beta protein rapidly accumulates in lipid rafts fol-
lowed by apolipoprotein E and phosphorylated tau accumu-
lation in the Tg2576 mouse model of Alzheimer's disease.  J
Neurosci 2004, 24(15):3801-3809.
8. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher
M, Ashe KH: A specific amyloid-beta protein assembly in the
brain impairs memory.  Nature 2006, 440(7082):352-357.
9. Kim SH, Tang YP, Sisodia SS: Abeta star: a light onto synaptic
dysfunction?  Nat Med 2006, 12(7):760-1; discussion 761.
10. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos
M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C,
Finch CE, Krafft GA, Klein WL: Diffusible, nonfibrillar ligands
derived from Abeta1-42 are potent central nervous system
neurotoxins.  Proc Natl Acad Sci U S A 1998, 95(11):6448-6453.
11. Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi
S, Pepeu G, Casamenti F: Beta-amyloid-induced inflammation
and cholinergic hypofunction in the rat brain in vivo: involve-
ment of the p38MAPK pathway.  Neurobiol Dis 2002,
11(2):257-274.
12. Abbas N, Bednar I, Mix E, Marie S, Paterson D, Ljungberg A, Morris
C, Winblad B, Nordberg A, Zhu J: Up-regulation of the inflam-
matory cytokines IFN-gamma and IL-12 and down-regula-
tion of IL-4 in cerebral cortex regions of APP(SWE)
transgenic mice.  J Neuroimmunol 2002, 126(1-2):50-57.
13. Dudal S, Morissette C, Lacombe D, Tremblay P, Gervais F: Differ-
ences in the amyloid-beta-induced inflammatory response in
microglia from C57BL/6 and A/J strains of mice.  J Neuroimmu-
nol 2004, 153(1-2):26-35.
14. Monsonego A, Imitola J, Zota V, Oida T, Weiner HL: Microglia-
mediated nitric oxide cytotoxicity of T cells following amy-Journal of Neuroinflammation 2008, 5:13 http://www.jneuroinflammation.com/content/5/1/13
Page 14 of 15
(page number not for citation purposes)
loid beta-peptide presentation to Th1 cells.  J Immunol 2003,
171(5):2216-2224.
15. Koenigsknecht J, Landreth G: Microglial phagocytosis of fibrillar
beta-amyloid through a beta1 integrin-dependent mecha-
nism.  J Neurosci 2004, 24(44):9838-9846.
16. Sheng JG, Mrak RE, Griffin WS: Neuritic plaque evolution in
Alzheimer's disease is accompanied by transition of acti-
vated microglia from primed to enlarged to phagocytic
forms.  Acta Neuropathol 1997, 94(1):1-5.
17. Fiala M, Cribbs DH, Rosenthal M, Bernard G: Phagocytosis of amy-
loid-beta and inflammation: two faces of innate immunity in
Alzheimer's disease.  J Alzheimers Dis 2007, 11(4):457-463.
18. Streit WJ: Microglial senescence: does the brain's immune sys-
tem have an expiration date?  Trends Neurosci 2006,
29(9):506-510.
19. Streit WJ: Microglia as neuroprotective, immunocompetent
cells of the CNS.  Glia 2002, 40(2):133-139.
20. Wyss-Coray T: Inflammation in Alzheimer disease: driving
force, bystander or beneficial response?  Nat Med 2006,
12(9):1005-1015.
21. Griffin WS: Inflammation and neurodegenerative diseases.
Am J Clin Nutr 2006, 83(2):470S-474S.
22. Griffin WS, Liu L, Li Y, Mrak RE, Barger SW: Interleukin-1 medi-
ates Alzheimer and Lewy body pathologies.  J Neuroinflamma-
tion 2006, 3:5.
23. Mrak RE, Griffin WS: Glia and their cytokines in progression of
neurodegeneration.  Neurobiol Aging 2005, 26(3):349-354.
24. Streit WJ, Mrak RE, Griffin WS: Microglia and neuroinflamma-
tion: a pathological perspective.  J Neuroinflammation 2004,
1(1):14.
25. Aloisi F, Ria F, Adorini L: Regulation of T-cell responses by CNS
antigen-presenting cells: different roles for microglia and
astrocytes.  Immunol Today 2000, 21(3):141-147.
26. Ethell DW, Shippy D, Cao C, Cracchiolo JR, Runfeldt M, Blake B,
Arendash GW: Abeta-specific T-cells reverse cognitive decline
and synaptic loss in Alzheimer's mice.  Neurobiol Dis 2006,
23(2):351-361.
27. Man SM, Ma YR, Shang DS, Zhao WD, Li B, Guo DW, Fang WG, Zhu
L, Chen YH: Peripheral T cells overexpress MIP-1alpha to
enhance its transendothelial migration in Alzheimer's dis-
ease.  Neurobiol Aging 2007, 28(4):485-496.
28. Monsonego A, Imitola J, Petrovic S, Zota V, Nemirovsky A, Baron R,
Fisher Y, Owens T, Weiner HL: Abeta-induced meningoen-
cephalitis is IFN-gamma-dependent and is associated with T
cell-dependent clearance of Abeta in a mouse model of
Alzheimer's disease.  Proc Natl Acad Sci U S A 2006,
103(13):5048-5053.
29. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S,
Taams LS: CD4+CD25+Foxp3+ regulatory T cells induce
alternative activation of human monocytes/macrophages.
Proc Natl Acad Sci U S A 2007, 104(49):19446-19451.
30. Kim WK, Alvarez X, Fisher J, Bronfin B, Westmoreland S, McLaurin
J, Williams K: CD163 identifies perivascular macrophages in
normal and viral encephalitic brains and potential precur-
sors to perivascular macrophages in blood.  Am J Pathol 2006,
168(3):822-834.
31. Galea I, Palin K, Newman TA, Van Rooijen N, Perry VH, Boche D:
Mannose receptor expression specifically reveals perivascu-
lar macrophages in normal, injured, and diseased mouse
brain.  Glia 2005, 49(3):375-384.
32. Simard AR, Rivest S: Neuroprotective properties of the innate
immune system and bone marrow stem cells in Alzheimer's
disease.  Mol Psychiatry 2006, 11(4):327-335.
33. Butovsky O, Talpalar AE, Ben-Yaakov K, Schwartz M: Activation of
microglia by aggregated beta-amyloid or lipopolysaccharide
impairs MHC-II expression and renders them cytotoxic
whereas IFN-gamma and IL-4 render them protective.  Mol
Cell Neurosci 2005, 29(3):381-393.
34. Butovsky O, Bukshpan S, Kunis G, Jung S, Schwartz M: Microglia can
be induced by IFN-gamma or IL-4 to express neural or den-
dritic-like markers.  Mol Cell Neurosci 2007, 35(3):490-500.
35. Butovsky O, Koronyo-Hamaoui M, Kunis G, Ophir E, Landa G, Cohen
H, Schwartz M: Glatiramer acetate fights against Alzheimer's
disease by inducing dendritic-like microglia expressing insu-
lin-like growth factor 1.  Proc Natl Acad Sci U S A 2006,
103(31):11784-11789.
36. Butovsky O, Ziv Y, Schwartz A, Landa G, Talpalar AE, Pluchino S,
Martino G, Schwartz M: Microglia activated by IL-4 or IFN-
gamma differentially induce neurogenesis and oligodendro-
genesis from adult stem/progenitor cells.  Mol Cell Neurosci
2006, 31(1):149-160.
37. Ziv Y, Ron N, Butovsky O, Landa G, Sudai E, Greenberg N, Cohen H,
Kipnis J, Schwartz M: Immune cells contribute to the mainte-
nance of neurogenesis and spatial learning abilities in adult-
hood.  Nat Neurosci 2006, 9(2):268-275.
38. Butovsky O, Kunis G, Koronyo-Hamaoui M, Schwartz M: Selective
ablation of bone marrow-derived dendritic cells increases
amyloid plaques in a mouse Alzheimer's disease model.  Eur
J Neurosci 2007, 26(2):413-416.
39. Herber DL, Mercer M, Roth LM, Symmonds K, Maloney J, Wilson N,
Freeman MJ, Morgan D, Gordon MN: Microglial activation is
required for Abeta clearance after intracranial injection of
lipopolysaccharide in APP transgenic mice.  J Neuroimmune
Pharmacol 2007, 2(2):222-231.
40. Vasilevko V, Xu F, Previti ML, Van Nostrand WE, Cribbs DH: Exper-
imental investigation of antibody-mediated clearance mech-
anisms of amyloid-beta in CNS of Tg-SwDI transgenic mice.
J Neurosci 2007, 27(49):13376-13383.
41. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D: Intra-
hippocampal LPS injections reduce Abeta load in APP+PS1
transgenic mice.  Neurobiol Aging 2001, 22(6):1007-1012.
42. Churchill JD, Galvez R, Colcombe S, Swain RA, Kramer AF, Green-
ough WT: Exercise, experience and the aging brain.  Neurobiol
Aging 2002, 23(5):941-955.
43. Cotman CW, Berchtold NC: Exercise: a behavioral intervention
to enhance brain health and plasticity.  Trends Neurosci 2002,
25(6):295-301.
44. Scarmeas N, Stern Y: Cognitive reserve and lifestyle.  J Clin Exp
Neuropsychol 2003, 25(5):625-633.
45. Colcombe SJ, Kramer AF, Erickson KI, Scalf P, McAuley E, Cohen NJ,
Webb A, Jerome GJ, Marquez DX, Elavsky S: Cardiovascular fit-
ness, cortical plasticity, and aging.  Proc Natl Acad Sci U S A 2004,
101(9):3316-3321.
46. McAuley E, Kramer AF, Colcombe SJ: Cardiovascular fitness and
neurocognitive function in older adults: a brief review.  Brain
Behav Immun 2004, 18(3):214-220.
47. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang
F, Cole G: Correlative memory deficits, Abeta elevation, and
amyloid plaques in transgenic mice [see comments].  Science
1996, 274(5284):99-102.
48. Arendash GW, King DL: Intra- and intertask relationships in a
behavioral test battery given to Tg2576 transgenic mice and
controls.  Physiol Behav 2002, 75(5):643-652.
49. Nichol KE, Parachikova AI, Cotman CW: Three weeks of running
wheel exposure improves cognitive performance in the aged
Tg2576 mouse.  Behav Brain Res 2007, 184(2):124-132.
50. Hulse RE, Kunkler PE, Fedynyshyn JP, Kraig RP: Optimization of
multiplexed bead-based cytokine immunoassays for rat
serum and brain tissue.  J Neurosci Methods 2004, 136(1):87-98.
51. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol
L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe
CG: Fibril specific, conformation dependent antibodies rec-
ognize a generic epitope common to amyloid fibrils and
fibrillar oligomers that is absent in prefibrillar oligomers.  Mol
Neurodegener 2007, 2(1):18.
52. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP:
Expression profiles for macrophage alternative activation
genes in AD and in mouse models of AD.  J Neuroinflammation
2006, 3:27.
53. Frenkel D, Maron R, Burt DS, Weiner HL: Nasal vaccination with
a proteosome-based adjuvant and glatiramer acetate clears
beta-amyloid in a mouse model of Alzheimer disease.  J Clin
Invest 2005, 115(9):2423-2433.
54. Streit WJ: Microglia and neuroprotection: implications for
Alzheimer's disease.  Brain Res Brain Res Rev 2005, 48(2):234-239.
55. Streit WJ, Conde JR, Fendrick SE, Flanary BE, Mariani CL: Role of
microglia in the central nervous system's immune response.
Neurol Res 2005, 27(7):685-691.
56. Griffin WS, Mrak RE: Interleukin-1 in the genesis and progres-
sion of and risk for development of neuronal degeneration in
Alzheimer's disease.  J Leukoc Biol 2002, 72(2):233-238.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Neuroinflammation 2008, 5:13 http://www.jneuroinflammation.com/content/5/1/13
Page 15 of 15
(page number not for citation purposes)
57. Munoz L, Ranaivo HR, Roy SM, Hu W, Craft JM, McNamara LK, Chico
LW, Van Eldik LJ, Watterson DM: A novel p38 alpha MAPK inhib-
itor suppresses brain proinflammatory cytokine up-regula-
tion and attenuates synaptic dysfunction and behavioral
deficits in an Alzheimer's disease mouse model.  J Neuroinflam-
mation 2007, 4:21.
58. Simard AR, Rivest S: [Bone marrow stem cells to the rescue of
Alzheimer's disease].  Med Sci (Paris) 2006, 22(10):822-824.
59. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S: Bone marrow-
derived microglia play a critical role in restricting senile
plaque formation in Alzheimer's disease.  Neuron 2006,
49(4):489-502.
60. Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way
D, Weinand M, Witte M, Lorton D, Kuo YM, Roher AE: Amyloid-
beta induces chemokine secretion and monocyte migration
across a human blood--brain barrier model.  Mol Med 1998,
4(7):480-489.
61. Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters
HV:  Cyclooxygenase-2-positive macrophages infiltrate the
Alzheimer's disease brain and damage the blood-brain bar-
rier.  Eur J Clin Invest 2002, 32(5):360-371.
62. Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M,
Heikenwalder M, Bruck W, Priller J, Prinz M: Microglia in the adult
brain arise from Ly-6C(hi)CCR2(+) monocytes only under
defined host conditions.  Nat Neurosci 2007, 10(12):1544-1553.
63. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM: Local self-
renewal can sustain CNS microglia maintenance and func-
tion throughout adult life.  Nat Neurosci 2007, 10(12):1538-1543.
64. Simard AR, Rivest S: Bone marrow stem cells have the ability
to populate the entire central nervous system into fully dif-
ferentiated parenchymal microglia.  Faseb J 2004,
18(9):998-1000.
65. Paul J, Strickland S, Melchor JP: Fibrin deposition accelerates
neurovascular damage and neuroinflammation in mouse
models of Alzheimer's disease.  J Exp Med 2007,
204(8):1999-2008.
66. Algotsson A, Winblad B: The integrity of the blood-brain bar-
rier in Alzheimer's disease.  Acta Neurol Scand 2007,
115(6):403-408.
67. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn
JF: Blood-brain barrier impairment in Alzheimer disease: sta-
bility and functional significance.  Neurology 2007,
68(21):1809-1814.
68. Floden AM, Combs CK: Beta-amyloid stimulates murine post-
natal and adult microglia cultures in a unique manner.  J Neu-
rosci 2006, 26(17):4644-4648.
69. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD:
Scavenger receptor-mediated adhesion of microglia to beta-
amyloid fibrils.  Nature 1996, 382(6593):716-719.
70. El Khoury J, Hickman SE, Thomas CA, Loike JD, Silverstein SC:
Microglia, scavenger receptors, and the pathogenesis of
Alzheimer's disease.  Neurobiol Aging 1998, 19(1 Suppl):S81-4.
71. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM: Brain
to plasma amyloid-beta efflux: a measure of brain amyloid
burden in a mouse model of Alzheimer's disease.  Science
2002, 295(5563):2264-2267.
72. DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM,
Holtzman DM: Plaque-associated disruption of CSF and
plasma amyloid-beta (Abeta) equilibrium in a mouse model
of Alzheimer's disease.  J Neurochem 2002, 81(2):229-236.
73. Lanz TA, Schachter JB: Solid-phase extraction enhances detec-
tion of beta-amyloid peptides in plasma and enables Abeta
quantification following passive immunization with Abeta
antibodies.  J Neurosci Methods 2007.